Literature DB >> 10074872

Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs.

M S Bauer1, A M Callahan, C Jampala, F Petty, M Sajatovic, V Schaefer, B Wittlin, B J Powell.   

Abstract

BACKGROUND: For the last several years, the Department of Veterans Affairs (VA) has been involved in the development of practice guidelines for major medical, surgical, and mental disorders. This article describes the development and content of the VA-Clinical Practice Guidelines for Bipolar Disorder, which are available in their entirety on the Journal Web site (http://www. psychiatrist.com).
METHOD: A multidisciplinary work group composed of content experts in the field of bipolar disorder and practitioners in general clinical practice was convened by the VA's Office of Performance and Quality and the Mental Health Strategic Health Group. The work group was instructed in algorithm development and methods of evidence evaluation. Draft guidelines were developed over the course of 6 months of meetings and conference calls, and that draft was then sent to nationally prominent content experts for final critique.
RESULTS: The Bipolar Guidelines are part of the family of the VA Clinical Guidelines for Management of Persons with Psychosis and consist of explicit algorithms supplemented by annotations that explain the specific decision points and their basis in the scientific literature. The guidelines are organized into 5 modules: a Core Module for diagnosis and assignment to mood state plus 4 treatment modules (Manic/Hypomanic/Mixed Episode, Bipolar Depressive Episode, Rapid Cycling, and Bipolar Disorder With Psychotic Features). The modules specify particular diagnostic and treatment tasks at each step, including both somatotherapeutic and psychotherapeutic interventions.
CONCLUSION: The VA Bipolar Guidelines are designed for easy clinical reference in decision making with individual patients, as well as for use as a scholarly reference tool. They also have utility in training activities and quality improvement programs.

Entities:  

Mesh:

Year:  1999        PMID: 10074872     DOI: 10.4088/jcp.v60n0104

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  22 in total

1.  Guidelines for treatment of bipolar disorder.

Authors:  E B Dennehy
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

Review 2.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 3.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

4.  Changes in the quality of care for bipolar I disorder during the 1990s.

Authors:  Alisa B Busch; Davina Ling; Richard G Frank; Shelly F Greenfield
Journal:  Psychiatr Serv       Date:  2007-01       Impact factor: 3.084

5.  Psychotherapy use in a privately insured population of patients diagnosed with a mental disorder.

Authors:  Ilan Harpaz-Rotem; Daniel Libby; Robert A Rosenheck
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-02-16       Impact factor: 4.328

Review 6.  [Treatment options for bipolar mania].

Authors:  T Attarbaschi; S Kasper
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

Review 7.  Predictive animal models of mania: hits, misses and future directions.

Authors:  Jared W Young; Brook L Henry; Mark A Geyer
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

8.  Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder.

Authors:  Jay D Amsterdam; Lola Luo; Justine Shults
Journal:  Br J Psychiatry       Date:  2012-10-25       Impact factor: 9.319

Review 9.  Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review.

Authors:  Hans-Jürgen Möller; Heinz Grunze; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-04       Impact factor: 5.270

Review 10.  Bipolar spectrum disorders. New perspectives.

Authors:  Andre Piver; Lakshmi N Yatham; Raymond W Lam
Journal:  Can Fam Physician       Date:  2002-05       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.